Alpha Tau MedicalDRTS +4.67%28 PB Ratio is 17.19 as of Jul. 05, 2026. GuruFocus rates DRTS with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 1,230 Biotechnology companies, Alpha Tau Medical ranks worse than 91.63% on this metric.
The historical rank and industry rank for Alpha Tau Medical's PB Ratio or its related term are showing as below:
DRTS'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 17.19
Current: 17.19
During the past 7 years, Alpha Tau Medical's highest PB Ratio was 17.19. The lowest was 0.00. And the median was 0.00.
DRTS's PB Ratio is ranked worse than 91.63% of 1230
companies
in the Biotechnology industry
Industry Median: 2.98
vs DRTS: 17.19
During the past 12 months, Alpha Tau Medical's average Book Value Per Share Growth Rate was -1.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -16.90% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Alpha Tau Medical was -16.90% per year. The lowest was -16.90% per year. And the median was -16.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Alpha Tau Medical PB Ratio Related Terms
Alpha Tau Medical PB Ratio Historical Data
* Premium members only.
The historical data trend for Alpha Tau Medical's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alpha Tau Medical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Tau Medical PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Tau Medical's PB Ratio distribution charts can be found below:
* The bar in red indicates where Alpha Tau Medical's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Alpha Tau Medical (DRTS) has a PB Ratio of 17.19 as of Jul. 05, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alpha Tau Medical and its competitors. According to the industry distribution chart, Alpha Tau Medical ranks #1127 out of 1230 companies in the Biotechnology industry, placing it in the top 91.6%.
Is Alpha Tau Medical's PB Ratio too high?
Alpha Tau Medical's current PB Ratio is 17.19. The Biotechnology industry median PB Ratio is 2.98. Alpha Tau Medical's value of 17.19 is 476.8% above this industry median. Based on the distribution chart, Alpha Tau Medical ranks #1127 out of 1230 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alpha Tau Medical has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Tau Medical's PB Ratio compare to ORIC and OLMA?
According to the Biotechnology industry distribution chart, Alpha Tau Medical ranks #1127 out of 1230 companies for PB Ratio. This places Alpha Tau Medical in the lower half of its industry. The industry median PB Ratio is 2.98. Alpha Tau Medical's value of 17.19 is 476.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.98, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alpha Tau Medical's current PB Ratio of 17.19 is 476.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Alpha Tau Medical and its competitors. For the Biotechnology industry, the median PB Ratio is 2.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Tau Medical's current PB Ratio is 17.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Tau Medical stock overvalued right now?
Alpha Tau Medical (DRTS) has a current PB Ratio of 17.19. The current PB Ratio is 17.19 and 476.8% above the Biotechnology industry median of 2.98. Alpha Tau Medical's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Alpha Tau Medical (DRTS), the current PB Ratio is 17.19 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
28GF Score
Get the complete analysis for DRTS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRTS has been successfully added to your 
